Physician profile
Aaron C Miller
NPI 1760724223
$110,535.90
in general payments reported to CMS, 2019-2025
12 companies · $47K in 2025
The $47K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $35.18 · 2021: $190 · 2022: $15K · 2023: $16K · 2024: $32K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $71K · Travel and Lodging: $12K · Consulting Fee: $6,695 · Food and Beverage: $5,621 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $70,840.00 |
| Travel and Lodging | $11,924.18 |
| Consulting Fee | $6,695.00 |
| Food and Beverage | $5,621.21 |
| Education | $191.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $66,345.09 | 2023-2025 | Winrevair |
| Actelion Pharmaceuticals US, INC. | $40,970.30 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| United Therapeutics Corporation | $1,773.89 | 2019-2025 | Tyvaso, Tyvaso, Remodulin |
| Bayer Healthcare Pharmaceuticals INC. | $1,068.45 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $96.50 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.15 | 2024 | Lifevest |
| Philips North America LLC | $66.15 | 2022-2025 | (8874) Incourage, Vest Therapy Und |
| Takeda Pharmaceuticals U.S.A., INC. | $36.60 | 2022 | |
| Acist Medical Systems, INC. | $33.63 | 2025 | |
| Cordis US Corp. | $23.13 | 2025 | Mynx Control Venous |
| Baxter Healthcare | $19.49 | 2023 | Hillrom - Life 2000 Ventilation System |
| Astrazeneca Pharmaceuticals Lp | $15.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.